Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of GreenGene F in previously treated patients with severe hemophilia A
2013-004383-62Phase 3Terminated
- Sponsor
- GC Biopharma
- Start
- Nov 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of GreenGene F in hemophilia A, sponsored by GC Biopharma. Primary endpoints: Efficacy and Safety. Started Nov 2013; status: terminated.
02
Drugs
GreenGene F
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2013-004383-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004383-62.